Compare CAAS & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAAS | FATE |
|---|---|---|
| Founded | N/A | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.7M | 131.5M |
| IPO Year | N/A | 2013 |
| Metric | CAAS | FATE |
|---|---|---|
| Price | $4.35 | $1.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.92 |
| AVG Volume (30 Days) | 26.9K | ★ 1.1M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.68 | N/A |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $725,260,000.00 | $7,137,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.87 | ★ N/A |
| Revenue Growth | ★ 16.72 | N/A |
| 52 Week Low | $3.50 | $0.66 |
| 52 Week High | $5.37 | $2.02 |
| Indicator | CAAS | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 56.88 | 46.03 |
| Support Level | $4.06 | $1.03 |
| Resistance Level | $4.43 | $1.19 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 75.56 | 36.71 |
China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.